Acrotech BioPharma
- Company typePrivate
- Founded2018
- HeadquartersWindsor, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Acrotech BioPharma does
Acrotech BioPharma Inc. is a US specialty pharmaceutical company founded in 2018 and headquartered in East Windsor, New Jersey. It is a wholly owned subsidiary of Aurobindo Pharma USA, Inc., which sits within Aurobindo Pharma Ltd. — the largest generic pharmaceutical company in the United States by volume, with $3.1B of global revenue in FY23. Acrotech was created as a distinct global platform to develop and commercialize innovative proprietary medications, deliberately separated from Aurobindo's generics franchise. Its therapeutic focus is oncology (hematological malignancies and rare solid tumors) and, more recently, dermatology (immunology-related skin conditions).
The company's commercial portfolio comprises seven FDA-approved products: Beleodaq (belinostat) for peripheral T-cell lymphoma; Folotyn (pralatrexate) for relapsed/refractory peripheral T-cell lymphoma; Zevalin (ibritumomab tiuxetan) for relapsed/refractory B-cell non-Hodgkin lymphoma; Evomela (melphalan) for multiple myeloma conditioning; Khapzory (levoleucovorin) for methotrexate rescue; Ryzneuta (efbemalenograstim alfa-vuxw) for chemotherapy-induced neutropenia; and the newly approved ADQUEY (difamilast ointment 1%), a PDE4 inhibitor for mild-to-moderate atopic dermatitis. The portfolio is sourced through a mix of asset acquisitions (Beleodaq, Folotyn, Zevalin, Evomela, Khapzory) and licensing deals (Ryzneuta from Evive; Adquey cleared Feb 2026), reflecting an in-license and commercialize model rather than de novo drug discovery.
Acrotech generates revenue through pharmaceutical product sales distributed via a dedicated field force of Medical Science Liaisons (MSLs) and Oncology Account Managers (OAMs), supplemented by licensing and partnership revenue (notably the Evive relationship for Ryzneuta). It also maintains a patient access program (acrotechpatientaccess.com) to support prescription fulfillment. Customers are US-based healthcare providers — principally oncologists, hematologists, and dermatologists — and the patients they treat. Marketing channels include MSL/OAM field engagement, major industry conferences (ASH, SOHO, Pan Pacific Lymphoma, ACCC, NCODA), and a corporate website and LinkedIn presence. The company employs 51–100 people and is privately held, with no public stock listing or independent venture funding identified.
Acrotech BioPharma firmographics
Firmographics- Name
- Acrotech BioPharma
- Legal name
- Acrotech Biopharma Inc.
- Website
- https://acrotechbiopharma.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Acrotech BioPharma industry classification
Industry- Product category
- Specialty Pharmaceuticals (Oncology and Dermatology)
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
- akta.pro secondary industries
- Dermatology Specialty Pharmaceuticals (HLAIACAL), Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)
Keywords
Where Acrotech BioPharma is headquartered
LocationHeadquarters
- HQ city
- Windsor
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Acrotech BioPharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain
Revenue model
- Pharmaceutical Product Sales: Commercialization of proprietary medications through direct sales to healthcare providers and through licensing/partnership agreements
- Licensing and Partnership Revenue: License agreements such as the Evive partnership for Ryzneuta commercialization in the United States
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
Acrotech BioPharma product offering
Product offeringCore offering
Acrotech BioPharma is a specialty pharmaceutical company that develops and commercializes innovative proprietary medications, primarily in oncology and dermatology. Its portfolio comprises seven approved pharmaceutical brands (Beleodaq, ADQUEY, Ryzneuta, Folotyn, Evomela, Khapzory, and Zevalin) addressing hematological malignancies, rare solid tumors, and immunology-related skin conditions, distributed through a direct field sales force and selective licensing partnerships.
Product overview
Acrotech BioPharma is a pharmaceutical company that serves as a global platform to develop and commercialize innovative proprietary medications, primarily in oncology and dermatology. The company operates a portfolio of acquired and licensed pharmaceutical brands rather than a unified platform architecture. The core product portfolio includes seven approved medications: Beleodaq (belinostat) for peripheral T-cell lymphoma, ADQUEY (difamilast) for atopic dermatitis, Ryzneuta (efbemalenograstim alfa-vuxw) for chemotherapy-induced neutropenia, Folotyn (pralatrexate) for T-cell lymphoma, Evomela (melphalan) for multiple myeloma, Khapzory (levoleucovorin) as a methotrexate rescue agent, and Zevalin (ibritumomab tiuxetan) for non-Hodgkin lymphoma. The company focuses on hematological malignancies, rare solid tumors, and immunology-related dermatology conditions.
Differentiator
Problem solved
Functional benefit
Products and services
- Beleodaq (belinostat) Beleodaq is a histone deacetylase inhibitor indicated for the treatment of peripheral T-cell lymphoma, prescribed by oncologists and administered in specialty oncology settings.
- ADQUEY (difamilast ointment 1%)
- Ryzneuta (efbemalenograstim alfa-vuxw)
- Folotyn (pralatrexate)
- Evomela (melphalan)
- Khapzory (levoleucovorin)
- Zevalin (ibritumomab tiuxetan)
Companies that use Acrotech BioPharma
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
Acrotech BioPharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Acrotech BioPharma partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- EvivecoreEvive entered a license agreement with Acrotech Biopharma to commercialize Ryzneuta (efbemalenograstim alfa-vuxw) in the United States. Evive received FDA approval for Ryzneuta for chemotherapy-induced neutropenia in November 2023. This partnership represents Acrotech's strategy of licensing-in and commercializing innovative therapies.
Scale indicators1 record
Recent moves4 records
Expansion highlights5 records
Acrotech BioPharma competitors and assessment
Company assessmentDirect peers
- Jazz Pharmaceuticals: Jazz Pharmaceuticals is a specialty biopharma focused on oncology (hematology/rare cancers) and neuroscience, commercializing a portfolio of differentiated branded assets — directly comparable to Acrotech's specialty pharma model with multiple in-line brands and a field-based commercial organization.
- Spectrum Pharmaceuticals: Spectrum Pharmaceuticals is a specialty oncology company commercializing branded hematology/oncology products, including several acquired and in-licensed assets, with a comparable business model of targeted field sales to oncologists.
- Helsinn Healthcare: Helsinn is a privately-held specialty pharma focused on oncology supportive care and rare cancers, with a license-in/commercialization model that closely mirrors Acrotech's strategy of partnering to bring differentiated assets to market.
- Puma Biotechnology: Puma Biotechnology is a specialty biopharma commercializing oncology products through a focused field sales force targeting oncologists, comparable in scale and commercial motion to Acrotech's oncology portfolio.
- Verastem Oncology: Verastem is a commercial-stage oncology company focused on hematologic malignancies and rare cancers, sharing Acrotech's emphasis on smaller patient populations and specialty distribution channels.
- CTI BioPharma: CTI BioPharma was a specialty oncology company focused on hematology/rare cancers before its acquisition by Sobi, representing a similar small-cap, single-therapeutic-area specialty commercial model to Acrotech's oncology franchise.
- LEO Pharma: LEO Pharma is a specialty dermatology company developing and commercializing treatments for skin conditions including atopic dermatitis, making it the closest dermatology-direct peer to Acrotech's Adquey franchise.
- Anacor Pharmaceuticals (acquired by Pfizer): Anacor developed crisaborole (Eucrisa), the first FDA-approved topical PDE4 inhibitor for atopic dermatitis — directly comparable mechanism and indication to Acrotech's Adquey (difamilast). Acquired by Pfizer in 2016.
Broad incumbents
- Aurobindo Pharma: Aurobindo Pharma is the parent of Acrotech Biopharma and the largest generic pharmaceutical company in the US; it provides the capital, manufacturing, and supply chain infrastructure that Acrotech leverages, and represents the broader corporate context in which Acrotech operates.
Others
- Evive Biotech: Evive is the originator of Ryzneuta (efbemalenograstim alfa-vuxw) and Acrotech's licensing partner for US commercialization — directly relevant as the counterparty in Acrotech's flagship licensing deal and as a benchmark for sourcing additional in-licensing opportunities.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Acrotech BioPharma social profiles
Digital presenceAcrotech BioPharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Acrotech BioPharma leadership team
Management profileNumber of profiles
Acrotech BioPharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Acrotech BioPharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Acrotech BioPharma
What does Acrotech BioPharma do?
Acrotech BioPharma is a specialty pharmaceutical company that develops and commercializes innovative proprietary medications, primarily in oncology and dermatology. Its portfolio comprises seven approved pharmaceutical brands (Beleodaq, ADQUEY, Ryzneuta, Folotyn, Evomela, Khapzory, and Zevalin) addressing hematological malignancies, rare solid tumors, and immunology-related skin conditions, distributed through a direct field sales force and selective licensing partnerships.
Is Acrotech BioPharma a public or private company?
Acrotech BioPharma is a private company. It is classified as corporate owned and is currently operating.
When was Acrotech BioPharma founded?
Acrotech BioPharma was founded in 2018. It employs 51 to 100 people.
Where is Acrotech BioPharma based?
Acrotech BioPharma is headquartered in Windsor, United States, in the North America region.
How does Acrotech BioPharma make money?
Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensing and Partnership Revenue.
Who are Acrotech BioPharma's main competitors?
Direct peers on record are Jazz Pharmaceuticals, Spectrum Pharmaceuticals, Helsinn Healthcare, Puma Biotechnology, Verastem Oncology, CTI BioPharma, LEO Pharma and Anacor Pharmaceuticals (acquired by Pfizer). Aurobindo Pharma is listed as a broad incumbent. Evive Biotech is listed as an others.
Does Acrotech BioPharma have an API?
No public API is recorded for Acrotech BioPharma.
What industry is Acrotech BioPharma in?
Acrotech BioPharma's product category is Specialty Pharmaceuticals (Oncology and Dermatology). Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIACAL, Dermatology Specialty Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.